Xenon Pharmaceuticals (NasdaqGM:XENE) Q3 2025 Earnings Call November 03, 2025 04:30 PM ET Speaker3Good day, everyone, and thank you for standing by. My name is RG, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2025 Xenon Pharmaceuticals earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-066 ...

Xenon Reports Third Quarter 2025 Financial Results & Business Update VANCOUVER, BC and BOSTON, MA, November 3, 2025 – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the third quarter ended September 30, 2025 and provided a business update. "We are entering an important, catalyst-rich period for Xenon. We ...

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xeno ...

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [3] - The company is advancing its lead molecule, azetukalner, which is a selective Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [3] - Additionally, Xenon is developing an early-stage portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for pain treatment [3] Upcoming Financial Results - Xenon Pharmaceuticals will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on November 3, 2025 [1] - A conference call and webcast will take place on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time) [2] Contact Information - Colleen Alabiso is the Senior Vice President of Corporate Affairs, and can be reached at (617) 671-9238 [5] - Media inquiries can be directed to media@xenon-pharma.com, while investor inquiries can be sent to investors@xenon-pharma.com [5]

Core Insights - Xenon Pharmaceuticals Inc. has appointed Tucker Kelly as Chief Financial Officer, bringing extensive strategic and commercial finance expertise to the company as it prepares for the commercialization of its lead candidate, azetukalner [1][2] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [4] - The company is advancing azetukalner, a selective Kv7 potassium channel opener, currently in Phase 3 clinical trials for epilepsy, major depressive disorder, and bipolar depression [5] Leadership Appointment - Tucker Kelly has over 25 years of experience in corporate and financial strategy for life sciences companies, previously serving as Executive Vice President, CFO, and Treasurer at Deciphera Pharmaceuticals [2] - His role at Deciphera included overseeing the company's growth and strategic financial planning, culminating in a $2.4 billion acquisition by Ono Pharmaceuticals in 2024 [2] Compensation Details - In connection with his appointment, Mr. Kelly was granted an option to purchase 225,000 common shares at an exercise price of $41.90, with shares vesting over four years [3] - Additionally, he received 30,000 restricted share units (RSUs) that will vest over four years, subject to his continued service with the company [3]

Core Viewpoint - The investor webinar focuses on Xenon Pharmaceuticals' Kv7 and Nav1.7 programs aimed at pain treatment, highlighting the company's leadership in ion channel drug development [1][4]. Company Overview - Ian Mortimer serves as the President and CEO of Xenon Pharmaceuticals and is moderating the session [1]. - The company has a strong pipeline and a history of positioning itself as a leader in ion channel drug development [4]. Key Personnel - Dr. Jim Empfield, Executive Vice President of Drug Discovery, will discuss Xenon's history and its advancements in drug development [3][4]. - Dr. JP Gilbert, Senior Director of Biology, and Dr. Chris Kenney, Chief Medical Officer, are also part of the speaking team [3].

Xenon Pharmaceuticals Conference Call Summary Company Overview - **Company**: Xenon Pharmaceuticals (NasdaqGM:XENE) - **Focus**: Neuroscience-focused biopharmaceutical company specializing in small molecule ion channel drug discovery and development [3][4][6] Key Points Pipeline and Development - **Lead Molecule**: Azetucaner, a KV7 channel opener, is in phase III development for epilepsy and depression, representing the most advanced potassium channel modulator in late-stage clinical development [3][4][8] - **Indications**: Azetucaner is being developed for four distinct indications: focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression [4] - **Early-Stage Pipeline**: The company is advancing a robust early-stage pipeline targeting both potassium and sodium channels, particularly KV7 and NAV1.7 for pain management [5][11] Pain Management Focus - **Pain Programs**: Xenon is focusing on developing KV7 potentiators and NAV1.7 inhibitors as non-opioid approaches for pain treatment [5][24] - **Clinical Trials**: Both lead compounds, XEN1120 (KV7) and XEN1701 (NAV1.7), are currently in phase I clinical studies [59][54] Scientific Insights - **Pain Signaling Pathway**: Pain signals originate in tissues and travel through dorsal root ganglion neurons to the spinal cord, where they are processed and relayed to the brain [16][17] - **Mechanism of Action**: KV7 channels regulate neuronal excitability, while NAV1.7 channels are critical for action potential initiation. Modulating these channels could significantly impact pain signaling [18][20][24] Genetic Validation - **NAV1.7 Target**: Loss of function mutations in the SCN9A gene (encoding NAV1.7) lead to congenital insensitivity to pain, validating NAV1.7 as a compelling target for pain treatment [33][53] - **Receptor Occupancy**: Recent findings suggest that 75% to 85% receptor occupancy of NAV1.7 is sufficient for pain relief, contrasting with previous beliefs that near 100% was necessary [38][64] Competitive Landscape - **Current Pain Treatments**: Existing options like NSAIDs and opioids have significant limitations, including risks of addiction and poor tolerability. There is a strong demand for non-opioid alternatives [57][60] - **Physician Insights**: Clinicians express a desire for mechanism-based innovations that can provide effective pain relief without the risks associated with current treatments [58][59] Future Plans - **Clinical Development**: Plans to initiate phase II proof-of-concept studies for both lead compounds next year [59] - **Ongoing Research**: Continued exploration of additional KV7 and NAV1.7 compounds to expand the pipeline and address various pain conditions [59][54] Additional Important Insights - **Collaboration and Expertise**: Xenon has established collaborations with major biopharmaceutical companies and has built a strong internal team focused on ion channel drug discovery [8][10] - **Preclinical Data**: Promising preclinical data supports the efficacy of KV7 openers in both acute and chronic pain models, indicating potential for significant therapeutic impact [30][31] This summary encapsulates the key points discussed during the conference call, highlighting Xenon Pharmaceuticals' strategic focus on pain management through innovative ion channel modulation.

Core Insights - Xenon Pharmaceuticals Inc. is hosting an investor webinar on October 6, 2025, to discuss its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain [1][2]. Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company engaged in drug discovery, clinical development, and commercialization of therapeutics for patients in need [4]. - The company's lead molecule, azetukalner, is a selective Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [4]. - Xenon is also advancing a portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for pain treatment [4]. Webinar Details - The webinar will take place from 11:30 AM to 12:30 PM Eastern Time, and participants can submit questions via chat or email [2]. - A live webcast will be available on the "Investors" section of Xenon's website, with a replay posted after the event [3].

Company Overview - Xenon Pharmaceuticals reported a loss of $1.07 per share for Q2 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.03, compared to a loss of $0.75 per share in the same quarter last year [3] - The company did not generate any revenues in the reported quarter, similar to the year-ago quarter, due to the absence of a marketed product [4] Financial Performance - Research and development (R&D) expenses increased by 51% year over year to $75 million, driven by costs related to ongoing studies and a larger workforce [5] - General and administrative expenses were $19.2 million, remaining relatively flat year over year [5] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $624.8 million, down from $691.1 million as of March 31, 2025 [6] Market Sentiment - There has been a downward trend in estimates revision for Xenon Pharmaceuticals over the past month [7] - The company has a poor Growth Score of F and a Momentum Score of D, resulting in an aggregate VGM Score of F [8] Industry Context - Xenon Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where Intellia Therapeutics, a peer, gained 9.4% over the past month [10] - Intellia Therapeutics reported revenues of $14.24 million for the last quarter, reflecting a year-over-year change of +104.6% [11]